卵巢癌临床治疗的研究进展

doi:10.12280/gjfckx.20210103

摘要/Abstract

摘要：

卵巢癌是死亡率最高的女性生殖系统恶性肿瘤,该疾病早期临床症状不明显,多数就诊时已处于晚期阶段。且由于复发和化疗的耐药性,使得其预后较差,严重威胁女性生命健康,这导致卵巢癌临床治疗面临着艰巨挑战。卵巢癌传统治疗手段是手术治疗加辅助化疗,近年来随着手术方式的改进、化疗方法的不断完善以及靶向药物的应用,卵巢癌的治疗方案不断丰富,虽然从一定程度上改善了卵巢癌预后,但是其总体生存率仍较差。此外,免疫疗法可利用自身免疫系统发挥作用,近年来在卵巢癌治疗中得到了广泛关注,但其临床应用仍需进行深入探索。因此,进一步优化卵巢癌的治疗方法,提高患者的生存率并改善其预后,是卵巢癌治疗的重点和难点。综述卵巢癌临床治疗现状及最新进展,以期为卵巢癌治疗提供新思路,并进一步改善其预后。

关键词: 卵巢肿瘤, 妇科外科手术, 抗肿瘤联合化疗方案, 分子靶向治疗, 多（ADP核糖）聚合酶抑制剂, 免疫疗法

Abstract:

Ovarian cancer is a malignant tumor of the female reproductive system with the highest mortality rate. The early clinical symptoms of the disease are not obvious, and most of them are in the advanced stage at the time of consultation. In addition, due to recurrence and chemotherapy resistance, the prognosis is poor. It seriously threatens women′s life and health, which leads to arduous challenges in the clinical treatment of ovarian cancer. The traditional treatment of ovarian cancer is surgical treatment plus adjuvant chemotherapy. In recent years, with the improvement of surgical methods, the continuous improvement of chemotherapy regimens and the application of targeted drugs, the treatment of ovarian cancer has been continuously enriched. Although it has improved the prognosis of ovarian cancer to a certain extent, its overall survival rate is still poor. In addition, immunotherapy can take advantage of the autoimmune system. In recent years, it has received extensive attention in the treatment of ovarian cancer, but its clinical application still needs to be explored in depth. Therefore, further optimizing the treatment of ovarian cancer, increasing the survival rate of patients and improving their prognosis are the most difficult points in the treatment of ovarian cancer. The current status and latest progress of clinical treatment of ovarian cancer are reviewed, in order to provide new ideas for the treatment of ovarian cancer and further improve its prognosis.

Key words: Ovarian neoplasms, Gynecologic surgical procedures, Antineoplastic combined chemotherapy protocols, Molecular targeted therapy, Poly(ADP-ribose) polymerase inhibitors, Immunotherapy

储慧慧, 刘倩. 卵巢癌临床治疗的研究进展[J]. 国际妇产科学杂志, 2021, 48(4): 443-447.

CHU Hui-hui, LIU Qian. Research Progress in Clinical Treatment of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2021, 48(4): 443-447.

参考文献 35

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. doi: 10.3322/caac.21590. doi: 10.3322/caac.21590
[2]	Moore K, Colombo N, Scambia G, et al. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer[J]. N Engl J Med, 2018, 379(26):2495-2505. doi: 10.1056/NEJMoa1810858. doi: 10.1056/NEJMoa1810858
[3]	Coleman RL, Fleming GF, Brady MF, et al. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer[J]. N Engl J Med, 2019, 381(25):2403-2415. doi: 10.1056/NEJMoa1909707. doi: 10.1056/NEJMoa1909707
[4]	van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer[J]. N Engl J Med, 2018, 378(3):230-240. doi: 10.1056/NEJMoa1708618. doi: 10.1056/NEJMoa1708618
[5]	Rocconi RP, Grosen EA, Ghamande SA, et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): a randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Oncol, 2020, 21(12):1661-1672. doi: 10.1016/S1470-2045(20)30533-7. doi: 10.1016/S1470-2045(20)30533-7
[6]	Facer B, Wang F, Grijalva CG, et al. Survival outcomes for robotic-assisted laparoscopy versus traditional laparoscopy in clinical stage I epithelial ovarian cancer[J]. Am J Obstet Gynecol, 2020, 222(5):474.e1-e12. doi: 10.1016/j.ajog.2019.10.104. doi: 10.1016/j.ajog.2019.10.104
[7]	佘宇佳, 叶明侠, 孟元光. 机器人、腹腔镜与开腹手术治疗卵巢癌的疗效比较[J]. 解放军医学院学报, 2020, 41(4):320-323. doi: 10.3969/j.issn.2095-5227.2020.04.002. doi: 10.3969/j.issn.2095-5227.2020.04.002
[8]	Nishio S, Ushijima K. Clinical significance of primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery in advanced ovarian cancer[J]. Jpn J Clin Oncol, 2020, 50(4):379-386. doi: 10.1093/jjco/hyaa015. doi: 10.1093/jjco/hyaa015 pmid: 32083282
[9]	Makar AP, Tropé CG, Tummers P, et al. Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer[J]. Oncologist, 2016, 21(6):745-754. doi: 10.1634/theoncologist.2015-0239. doi: 10.1634/theoncologist.2015-0239 pmid: 27009938
[10]	Onda T, Satoh T, Saito T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602[J]. Eur J Cancer, 2016, 64:22-31. doi: 10.1016/j.ejca.2016.05.017. doi: 10.1016/j.ejca.2016.05.017
[11]	Harter P, Sehouli J, Lorusso D, et al. A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms[J]. N Engl J Med, 2019, 380(9):822-832. doi: 10.1056/NEJMoa1808424. doi: 10.1056/NEJMoa1808424
[12]	Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019[J]. J Natl Compr Canc Netw, 2019, 17(8):896-909. doi: 10.6004/jnccn.2019.0039. doi: 10.6004/jnccn.2019.0039
[13]	Sehouli J, Grabowski JP. Surgery in recurrent ovarian cancer[J]. Cancer, 2019, 125(Suppl 24):4598-4601. doi: 10.1002/cncr.32511. doi: 10.1002/cncr.32511
[14]	Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine[J]. CA Cancer J Clin, 2019, 69(4):280-304. doi: 10.3322/caac.21559. doi: 10.3322/caac.21559
[15]	Bartels HC, Rogers AC, Postle J, et al. Morbidity and mortality in women with advanced ovarian cancer who underwent primary cytoreductive surgery compared to cytoreductive surgery for recurrent disease: a meta-analysis[J]. Pleura Peritoneum, 2019, 4(2):20190014. doi: 10.1515/pp-2019-0014. doi: 10.1515/pp-2019-0014 pmid: 31417960
[16]	Coleman RL, Spirtos NM, Enserro D, et al. Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer[J]. N Engl J Med, 2019, 381(20):1929-1939. doi: 10.1056/NEJMoa1902626. doi: 10.1056/NEJMoa1902626
[17]	Buechel M, Herzog TJ, Westin SN, et al. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option[J]. Ann Oncol, 2019, 30(5):721-732. doi: 10.1093/annonc/mdz104. doi: S0923-7534(19)31176-7 pmid: 31987339
[18]	Onda T, Satoh T, Ogawa G, et al. Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial[J]. Eur J Cancer, 2020, 130:114-125. doi: 10.1016/j.ejca.2020.02.020. doi: 10.1016/j.ejca.2020.02.020
[19]	Vergote I, Coens C, Nankivell M, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials[J]. Lancet Oncol, 2018, 19(12):1680-1687. doi: 10.1016/S1470-2045(18)30566-7. doi: S1470-2045(18)30566-7 pmid: 30413383
[20]	刘晓峰, 李玮, 佟芳. TC和PC化疗方案在晚期卵巢癌术后患者中的效果及安全性比较[J]. 医学综述, 2019, 25(21):4340-4344. doi: 10.3969/j.issn.1006-2084.2019.21.035. doi: 10.3969/j.issn.1006-2084.2019.21.035
[21]	Bartos A, Bartos D, Herdean A, et al. Hyperthermic intraperitoneal chemotherapy (HIPEC). Mechanisms of action and the role of HIPEC in the treatment of peritoneal carcinomatosis[J]. Ann Ital Chir, 2018, 89:513-527.
[22]	Ghirardi V, Ronsini C, Trozzi R, et al. Hyperthermic intraperitoneal chemotherapy in interval debulking surgery for advanced epithelial ovarian cancer: A single-center, real-life experience[J]. Cancer, 2020, 126(24):5256-5262. doi: 10.1002/cncr.33167. doi: 10.1002/cncr.33167
[23]	Zhang Y, Dong Y, Fu H, et al. Multifunctional tumor-targeted PLGA nanoparticles delivering Pt(IV)/siBIRC5 for US/MRI imaging and overcoming ovarian cancer resistance[J]. Biomaterials, 2021, 269:120478. doi: 10.1016/j.biomaterials.2020.120478. doi: 10.1016/j.biomaterials.2020.120478
[24]	Xiao Y, Lin FT, Lin WC. ACTL6A promotes repair of cisplatin-induced DNA damage, a new mechanism of platinum resistance in cancer[J]. Proc Natl Acad Sci U S A, 2021, 118(3):e2015808118. doi: 10.1073/pnas.2015808118. doi: 10.1073/pnas.2015808118
[25]	Mukherjee A, Huynh V, Gaines K, et al. Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin[J]. Cancer Res, 2019, 79(13):3185-3191. doi: 10.1158/0008-5472.CAN-19-0542. doi: 10.1158/0008-5472.CAN-19-0542 pmid: 31061066
[26]	Lee J, Cho YJ, Lee JW, et al. KSP siRNA/paclitaxel-loaded PEGylated cationic liposomes for overcoming resistance to KSP inhibitors: Synergistic antitumor effects in drug-resistant ovarian cancer[J]. J Control Release, 2020, 321:184-197. doi: 10.1016/j.jconrel.2020.02.013. doi: 10.1016/j.jconrel.2020.02.013
[27]	明茗, 辛妮, 张静静. 新辅助化疗与肿瘤减灭术治疗卵巢癌疗效和安全性的系统评价[J]. 中国计划生育和妇产科, 2020, 12(11):36-40. doi: 10.3969/j.issn.1674-4020.2020.11.11. doi: 10.3969/j.issn.1674-4020.2020.11.11
[28]	Min A, Im SA. PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation[J]. Cancers(Basel), 2020, 12(2):394. doi: 10.3390/cancers12020394. doi: 10.3390/cancers12020394
[29]	Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what's next after PARP inhibitors?[J]. Nat Rev Clin Oncol, 2018, 15(9):564-576. doi: 10.1038/s41571-018-0055-6. doi: 10.1038/s41571-018-0055-6 pmid: 29955114
[30]	Blessing C, Mandemaker IK, Gonzalez-Leal C, et al. The Oncogenic Helicase ALC1 Regulates PARP Inhibitor Potency by Trapping PARP2 at DNA Breaks[J]. Mol Cell, 2020, 80(5):862-875.e6. doi: 10.1016/j.molcel.2020.10.009. doi: 10.1016/j.molcel.2020.10.009
[31]	Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer[J]. Ann Oncol, 2019, 30(4):551-557. doi: 10.1093/annonc/mdz018. doi: S0923-7534(19)31114-7 pmid: 31987271
[32]	Pfisterer J, Shannon CM, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(5):699-709. doi: 10.1016/S1470-2045(20)30142-X. doi: S1470-2045(20)30142-X pmid: 32305099
[33]	Zhao Y, Lee CK, Lin CH, et al. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways[J]. Immunity, 2019, 51(6):1059-1073.e9. doi: 10.1016/j.immuni.2019.11.003. doi: 10.1016/j.immuni.2019.11.003
[34]	Balança CC, Scarlata CM, Michelas M, et al. Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial Malignancies[J]. Cancer Immunol Res, 2020, 8(7):869-882. doi: 10.1158/2326-6066.CIR-19-0855. doi: 10.1158/2326-6066.CIR-19-0855
[35]	Komura N, Mabuchi S, Shimura K, et al. The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer[J]. Cancer Immunol Immunother, 2020, 69(12):2477-2499. doi: 10.1007/s00262-020-02628-2. doi: 10.1007/s00262-020-02628-2